With a market capitalization of $19,531,964,862, Resmed Inc has a greater market value than 93.03% of US stocks.
RMD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 871.78 -- higher than 96.47% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Resmed Inc is higher than 94.01% of stocks in our set with a positive cash flow.
Stocks that are quantitatively similar to RMD, based on their financial statements, market capitalization, and price volatility, are A, CSGP, CERN, EBAY, and HPE.
RMD's SEC filings can be seen here. And to visit Resmed Inc's official web site, go to www.resmed.com.
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing. The company was founded in 1989 and is based in San Diego, California.
RMD Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Resmed Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Resmed Inc ranked in the 15th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Resmed Inc ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is 13.19; that's higher than 74.65% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately only 14.76% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
RMD's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.16% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
GMED, VAR, TECH, A, and ELMD can be thought of as valuation peers to RMD, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.